Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 114 clinical trials
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibitor.

b-cell small lymphocytic lymphoma
lymphoma
gilbert's syndrome
neutrophil count
platelet count
  • 0 views
  • 25 May, 2022
  • 3 locations
A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies or AML

This is a Phase 1, open-label, 3 + 3 dose escalation study to determine the safety and preliminary efficacy of voruciclib in subjects with relapsed/refractory B cell malignancies and AML after treatment with standard therapy.

marginal zone lymphoma
follicular lymphoma
measurable disease
mantle cell lymphoma
hodgkin's disease
  • 93 views
  • 24 Mar, 2022
  • 10 locations
A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

This is a Phase I/II, multicenter, open-label study to evaluate the safety, efficacy, tolerability, and pharmacokinetics of a novel BTK inhibitor, Orelabrutinib (ICP-022) in Patients with B-cell malignancies. The study contains two parts, Part 1 (dose escalation) and Part 2 (dose expansion).

renal function tests
marginal zone lymphoma
mantle cell lymphoma
measurable disease
lymphocytic leukemia
  • 72 views
  • 28 Feb, 2022
  • 27 locations
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

A Three-Arm Study of ME-401 in Subjects with Relapsed/Refractory CLL/SLL or FL, of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL

ct scan
hodgkin's disease
diffuse large b-cell lymphoma
ejection fraction
tyrosine
  • 280 views
  • 27 Jan, 2022
  • 23 locations
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.

prolymphocytic leukemia
b-cell small lymphocytic lymphoma
measurable disease
leukemia
monoclonal antibodies
  • 2 views
  • 10 Apr, 2022
  • 11 locations
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT). If patients achieve either complete, partial, or stable response following ASCT, they will receive an IV dose of Polatuzumab Vedotin once every 21 days until they receive 8 doses. After Polatuzumab …

nitrosoureas
renal function tests
marginal zone lymphoma
mantle cell lymphoma
diffuse lymphoma
  • 0 views
  • 13 Nov, 2021
  • 1 location
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

CLBR001 + SWI019 is an combination investigational immunotherapy being evaluated as a potential treatment for patients diagnosed with B cell malignancies who are refractory or unresponsive to salvage therapy or who cannot be considered for or have progressed after autologous hematopoietic cell transplantation. This first-in-human study will assess the safety …

tyrosine
bendamustine
cancer
cell transplantation
  • 5 views
  • 08 Dec, 2021
  • 8 locations
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human dose escalation and cohort expansion multicenter, open-label study designed to evaluate the safety and preliminary efficacy of NX-5948 in patients with advanced B-cell malignancies.

  • 0 views
  • 29 May, 2022
  • 2 locations
A Safety and Efficacy Study of ADI-001, an Anti-CD20 Allogeneic Gamma Delta CAR-T, in Subjects With B Cell Malignancies (GLEAN-1)

This is a Phase 1 dose esclation study following a 3+3 study design. The purpose of this study is to evaluate the safety and efficacy of ADI-001 in patients with B cell malignancies.

cyclophosphamide
fludarabine
bendamustine
  • 0 views
  • 19 Jun, 2022
  • 5 locations
An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

marginal zone lymphoma that has come back after treatment (relapsed) or has not responded to treatment (refractory). Venetoclax may stop the growth of cancer cells by blocking the action of a protein

low molecular weight heparin
hyaluronidase
venetoclax
measurable disease
monoclonal antibodies
  • 0 views
  • 23 Apr, 2022
  • 1 location